APA (7th ed.) Citation

Y, X., M, L., R, J., X, W., H, H., R, B., . . . L, L. (2025). Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors. Clinical pharmacokinetics, 64(6), 943. https://doi.org/10.1007/s40262-025-01521-4

Chicago Style (17th ed.) Citation

Y, Xu, et al. "Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors." Clinical Pharmacokinetics 64, no. 6 (2025): 943. https://doi.org/10.1007/s40262-025-01521-4.

MLA (9th ed.) Citation

Y, Xu, et al. "Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors." Clinical Pharmacokinetics, vol. 64, no. 6, 2025, p. 943, https://doi.org/10.1007/s40262-025-01521-4.